기사

Prodizen Co., Ltd., a cell therapy specialist led by CEO Sim Su-ja, has won the Grand Prize in the Medical category at the 2026 Korea Industry Awards. Meanwhile, its subsidiary Medisarang is strengthening its presence in Korea’s regenerative medicine market by signing a strategic memorandum of understanding (MOU) with Humedix, part of the Huons Group, to commercialize new PRP (platelet-rich plasma) kits and activation platforms.

The MOU between Medisarang and Humedix was signed on the 14th at the Huons Group headquarters in Seongnam, Gyeonggi Province, for the commercialization of PRP-based products and activation platforms.

Prodizen’s recent award reflects a comprehensive evaluation of its achievements, including the first commercialization of PRP in Korea, the registration of three new medical technologies, and exports to over 30 countries. Its subsidiary Medisarang, a pioneer in the field, registered Korea’s first PRP product with the Ministry of Food and Drug Safety in 2008 and continues to handle full-scale manufacturing in-house.

The Huons Group, founded in 1965, is a total healthcare group with multiple affiliates under its holding company, including Huons (pharmaceuticals), Humedix (aesthetics and biopharmaceuticals), Huons Meditech, and Huons Biopharma.

Humedix, known for its aesthetic portfolio such as hyaluronic acid (HA) fillers and botulinum toxin, plans to expand into PRP-based regenerative aesthetics through this partnership. Both companies intend to collaborate across the entire value chain—from growth factor and platelet extraction and activation device development to planning, marketing, distribution, and sales. CEO Kang Min-jong stated that the company aims to accelerate market entry and business expansion by leveraging synergies with its existing aesthetic product lineup, while CEO Sim Su-ja of Medisarang emphasized establishing a new standard in autologous blood-based therapies.

Founded in 1998, when the concept of cell therapy was still unfamiliar, Prodizen focused on developing technologies to concentrate and separate platelets from autologous blood. PRP is a regenerative medicine technology that extracts high concentrations of platelet-derived growth factors through centrifugation and reapplies them to the affected area.

Sim Su-ja, CEO of Prodizen

Today, PRP is widely used across orthopedics, obstetrics and gynecology, ophthalmology, and aesthetics. However, when Medisarang first entered the market in 2008, there were no commercialized PRP products in Korea. Prodizen pioneered the development and commercialization of PRP tubes without prior reference cases or market data.

Beyond market entry, institutional recognition posed a greater challenge. Prodizen overcame this through clinical validation, achieving official recognition as a new medical technology in three clinical fields—orthopedics, ophthalmology, and obstetrics and gynecology. Notably, the orthopedic designation in 2019 was achieved through joint R&D with Samsung Seoul Hospital, Catholic Hospital, and Chosun University Hospital, marking a first in Korea.

The company later expanded globally, obtaining U.S. FDA Class II clearance and European CE certification, and becoming the first in Korea to complete registrations in both the U.S. and China. From approximately USD 100,000 in exports in 2017, it rapidly grew to achieve USD 1 million in exports from a single PRP product line, earning the “$1 Million Export Tower” award in 2023. Currently exporting to over 30 countries, Prodizen aims to exceed USD 3 million in exports by 2027 through a sales agreement with Clarion Medical.

Prodizen has also introduced its next-generation PRP platform, GFC+ (Growth Factor Concentrate Plus). This innovative solution extracts and activates high concentrations of growth factors, enabling applications in skin elasticity improvement, scar and pigmentation treatment, and hair regeneration. By addressing limitations of conventional PRP procedures, GFC+ offers uniform growth factor concentration, enhanced cellular responsiveness, and improved safety, supported by multiple clinical data sets.

At KIMES 2026 held at COEX in Seoul from March 19 to 22, Prodizen stated that it has already completed registrations in most regions including the U.S., Canada, and Europe, and aims to expand further into Southeast Asia by securing new distribution partners. At the largest-ever exhibition with participation from 1,490 companies across 41 countries, the company actively engaged in direct consultations with medical institutions and global buyers based on its clinical data.

Moving forward, Prodizen plans to enhance clinical utilization through continuous technological advancement and product line expansion, improve accessibility for healthcare professionals through accumulated clinical data and educational programs, and gradually expand its export footprint through partnerships with global distribution networks. CEO Sim Su-ja stated, “We will continue to contribute to healthier lives through unwavering development of cell therapy technologies.”